ADC Therapeutics SA

ADCT Healthcare Biotechnology

ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.

1.41 0.08 −5.37%
Market cap
$190.2M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
5/9
Altman Z
−6.67
Beneish M
−2.09
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
— — — — — — 1 3 5
Altman Z-Score
— — — — (0.50) (2.23) (5.55) (6.61) (6.67)
P/S ratio
0.00 0.00 0.00 — 43.21 1.34 1.99 2.73 5.51
Altman Z″-Score (non-manufacturers)
— (2.14) (7.16) — (2.55) (4.04) (10.76) (13.96) (14.62)
P/FCF ratio
0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(47.62) (47.62) (47.62) — (25.15) (5.23) (4.37) (8.85) (14.41)
Beneish M-Score
— — 2.76 — — 1.36 (5.19) (2.67) (2.09)
P/B ratio
13.75 13.75 13.75 — 9.33 3.53 0.00 0.00 0.00
Price to Tangible BV
13.75 13.75 13.75 — 10.17 4.31 0.00 0.00 0.00
EV/Sales
0.00 0.00 0.00 — 33.88 0.36 (0.19) 0.99 3.72
EV/EBITDA
0.00 0.00 0.00 — 0.00 0.00 0.08 0.00 0.00
EV/Operating CF
(9.22) (9.22) (9.22) — (5.21) (0.55) 0.11 (0.57) (2.14)
EV/FCF
(9.19) (9.19) (9.19) — (5.06) (0.54) 0.11 (0.56) (2.15)
Quick Ratio
12.88 6.22 5.89 10.93 6.72 4.87 4.49 3.37 4.14
Current Ratio
12.91 6.36 6.15 11.14 7.10 5.31 4.97 3.62 4.37
Net Debt/EBITDA
2.88 1.11 0.94 1.51 1.29 1.69 1.02 1.08 1.22
Debt/Assets
0.00% 0.00% 3.65% 21.73% 21.31% 24.89% 31.77% 35.29% 35.73%
Debt/Equity
0.00 0.00 0.05 0.33 0.79 1.54 (0.76) (0.56) (0.62)
Asset Turnover
0.01 0.02 0.02 0.00 0.06 0.38 0.16 0.21 0.25
Operating CF/Net income
0.83 0.99 1.04 0.69 1.01 0.88 0.49 0.78 0.99
Capex/Depreciation
0.00 (3.34) (1.30) (1.28) (2.42) (1.01) (0.98) (0.26) 0.21
Interest Coverage
0.00 (44.10) (765.38) (44.51) (14.27) (3.36) (3.58) (2.60) (2.35)
ROE
(47.87%) (65.58%) (98.13%) (110.28%) (91.72%) (127.99%) 697.85% 89.97% 73.43%
ROA
(42.54%) (163.52%) (80.82%) (75.62%) (40.65%) (28.34%) (56.77%) (46.65%) (44.22%)
ROIC
0.00% 0.00% (11,733.39%) (1,729.42%) 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(36.56%) (101.51%) (111.96%) (59.83%) (50.52%) (44.09%) (87.53%) (73.12%) (60.39%)
Average Days of Receivables
390.10 61.47 310.09 0.00 325.19 126.89 132.14 104.68 130.63
Research and Development Expense of Revenue
4,732.45% 10,378.33% 4,595.60% 0.00% 465.85% 88.83% 182.76% 154.77% 127.84%
Selling, General and Administrative Expense of Revenue
432.95% 769.12% 606.92% 0.00% 401.69% 68.36% 152.23% 121.28% 98.25%
Intangible Assets out of Total Assets
0.00 0.04 0.06 0.02 0.02 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 41.14% 47.74% 0.00% 178.32% 23.50% 19.40% 9.27% 8.49%
Graham Net Nets
0.08 0.08 0.08 — 0.05 0.08 (1.21) (1.21) (0.45)
Graham Number
0.00 0.00 0.00 — 0.00 0.00 10.94 8.80 6.28
Earnings Yield
(2.17%) (2.17%) (2.17%) — (14.85%) (55.99%) (173.37%) (82.91%) (33.99%)
Free Cash Flow Yield
(10.08%) (10.08%) (10.08%) — (15.50%) (50.15%) (88.33%) (64.53%) (31.40%)
Revenue per Share
581.61 0.02 0.05 0.00 0.44 2.69 0.85 0.73 0.64
Operating CF per Share
(24,175.81) (2.60) (2.47) (2.58) (3.04) (1.77) (1.45) (1.27) (1.11)
Capex per Share
0.00 (0.05) (0.04) (0.04) (0.08) (0.03) (0.04) (0.01) 0.00
Free Cash Flow per Share
(24,175.81) (2.66) (2.51) (2.62) (3.12) (1.80) (1.49) (1.28) (1.11)
Cash per Share
84,758.71 2.98 2.34 6.71 6.08 4.18 3.41 2.58 2.06
Shareholders Equity per Share
80,376.13 2.71 2.26 5.13 2.16 1.02 (1.81) (2.09) (1.46)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
80,376.13 2.71 2.26 5.13 2.16 1.02 (1.81) (2.09) (1.46)
Free Cash Flow
(74.94) (123.83) (123.73) (171.54) (239.75) (140.72) (121.90) (124.70) (140.78)
Working Capital
244.63 119.73 102.66 410.01 451.25 353.04 268.62 210.79 236.17
Capital Expenditures
(3.16) (2.47) (2.15) (2.81) (6.38) (2.41) (3.22) (0.87) 0.40
Net Current Asset Value
242.39 117.77 96.08 272.26 73.30 23.57 (166.74) (233.37) (202.65)
EV/EBIT
0.00 0.00 0.00 — 0.00 0.00 0.08 0.00 0.00
Capex to Sales
0.00 2.17 0.92 0.00 0.19 0.01 0.05 0.01 0.00
Price to Operating Income
0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.30 0.48 1.20 1.34 0.65 0.71 0.58 0.65 0.00
Cash ROIC
(14.64%) (46.72%) (53.39%) (19.35%) (31.37%) (26.65%) (50.15%) (77.04%) (73.72%)
Accounts Receivable Turnover
0.99 1.08 2.15 0.00 2.06 4.07 1.42 3.11 3.29
Accounts Payable Turnover
0.00 0.00 0.00 0.46 0.16 0.27 0.18 0.35 0.43
Inventory Turnover
— — — 0.00 0.00 0.28 0.18 0.65 1.80
Average Days of Payables
0.00 0.00 0.00 977.10 3,165.25 1,365.68 2,247.01 1,106.17 577.59
Days of Inventory on Hand
— — — 0.00 2,914.24 1,334.94 2,334.76 138.11 263.39
Average Receivables
1.82 1.06 1.09 2.34 16.45 51.59 49.08 22.75 24.72
Average Payables
7.18 7.18 5.04 4.30 8.68 12.22 13.96 16.80 13.60
Average Inventory
— — — — — 11.60 14.13 9.21 3.22
Average Assets
211.25 75.28 144.12 325.69 565.83 554.42 422.82 338.38 322.57
Average Common Equity
187.70 187.70 118.70 223.33 250.80 122.77 (34.40) (175.45) (194.24)

Fold the line items

Columns are period end dates